ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.3333.

PRQR has been the topic of several recent analyst reports. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Oppenheimer began coverage on ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price target for the company. Weiss Ratings lowered ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Finally, Chardan Capital decreased their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th.

ProQR Therapeutics Trading Up 4.8%

Shares of PRQR stock opened at $1.76 on Friday. The company has a market capitalization of $185.43 million, a price-to-earnings ratio of -3.52 and a beta of 0.04. The firm has a 50-day moving average price of $1.61 and a 200 day moving average price of $1.68. ProQR Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, research analysts predict that ProQR Therapeutics will post -0.52 earnings per share for the current year.

Insider Activity

In other ProQR Therapeutics news, Director Bart Filius purchased 150,000 shares of the stock in a transaction on Friday, June 26th. The stock was bought at an average price of $1.54 per share, for a total transaction of $231,000.00. Following the acquisition, the director directly owned 150,000 shares of the company’s stock, valued at $231,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Boer Daniel Anton De purchased 150,000 shares of the stock in a transaction on Tuesday, July 7th. The stock was acquired at an average price of $1.59 per share, with a total value of $238,500.00. Following the acquisition, the chief executive officer directly owned 150,000 shares in the company, valued at $238,500. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after acquiring an additional 359,475 shares during the last quarter. Aberdeen Group plc increased its position in ProQR Therapeutics by 28.4% during the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock worth $5,960,000 after purchasing an additional 651,853 shares during the last quarter. Ikarian Capital LLC increased its position in ProQR Therapeutics by 67.2% during the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after purchasing an additional 600,000 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its stake in ProQR Therapeutics by 3.9% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,246,234 shares of the biopharmaceutical company’s stock worth $2,654,000 after purchasing an additional 46,596 shares during the period. Finally, Citadel Advisors LLC raised its stake in ProQR Therapeutics by 73.2% during the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 277,749 shares during the period. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.